Out with the old, in with the new: Could plasma exchange be used to fill a therapeutic gap in neurology?

Journal article

The global tally of neurological disorders is exponentially rising and yet effective therapies for most remain evasive. There is a great deal of research into novel small molecules, immunotherapies and gene therapies to fill this therapeutic gap. We believe greater focus on plasma exchange as a research and clinical tool may provide useful insight into pathological mechanisms and effective treatment strategies. Plasma exchange has been traditionally used to treat antibody-mediated neurological diseases, such as myasthenia gravis and neuromyelitis optica, but there could be much wider future potential uses in neurology. Plasma exchange is not antibody specific, as it also removes a variety of other plasma-soluble factors, including age-related and disease-associated neurotoxic proteins, such as fibrinogen and amyloid. As research develops into the role of blood-brain barrier and immunological alterations in diseases not typically regarded as immune-driven, interest in neurotoxic plasma proteins grows. Here, we highlight that plasma exchange may have uses outside of antibody-mediated neurological diseases, by removing neurotoxic proteins from the systemic circulation.

Authors: Spencer, JI; Crane, M; Pisa, M; Waldman, AD; DeLuca, GC

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Journal of the Neurological Sciences
• Volume: 432
• Article number: 120056
• Publication date: 2021-11-11
• Acceptance date: 2021-11-08
• DOI: 10.1016/j.jns.2021.120056
• EISSN: 1878-5883
• ISSN: 0022-510X
• Pmid: 34823869
• Language: English
• Keywords: myasthenia gravis; plasmapheresis; neuromyelitis optica; neurology; plasma exchange; humans; FFR